These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1358654)

  • 21. Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue.
    Schmidt CJ; Wu L; Lovenberg W
    Eur J Pharmacol; 1986 May; 124(1-2):175-8. PubMed ID: 2424776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons.
    Schmidt CJ; Taylor VL
    Eur J Pharmacol; 1988 Oct; 156(1):121-31. PubMed ID: 2463176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective 5-hydroxytryptamine2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats.
    Schmidt CJ; Abbate GM; Black CK; Taylor VL
    J Pharmacol Exp Ther; 1990 Nov; 255(2):478-83. PubMed ID: 1978728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
    McKenna DJ; Peroutka SJ
    J Neurochem; 1990 Jan; 54(1):14-22. PubMed ID: 1967141
    [No Abstract]   [Full Text] [Related]  

  • 25. Short-term effects of 2,4,5-trihydroxyamphetamine, 2,4,5-trihydroxymethamphetamine and 3,4-dihydroxymethamphetamine on central tryptophan hydroxylase activity.
    Elayan I; Gibb JW; Hanson GR; Lim HK; Foltz RL; Johnson M
    J Pharmacol Exp Ther; 1993 May; 265(2):813-8. PubMed ID: 8496826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat.
    Hekmatpanah CR; McKenna DJ; Peroutka SJ
    Neurosci Lett; 1989 Sep; 104(1-2):178-82. PubMed ID: 2573011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion.
    Chu T; Kumagai Y; DiStefano EW; Cho AK
    Biochem Pharmacol; 1996 Mar; 51(6):789-96. PubMed ID: 8602874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of MK-801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog.
    Johnson M; Hanson GR; Gibb JW
    Eur J Pharmacol; 1989 Jun; 165(2-3):315-8. PubMed ID: 2570704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain.
    Schmidt CJ; Levin JA; Lovenberg W
    Biochem Pharmacol; 1987 Mar; 36(5):747-55. PubMed ID: 2881549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration.
    Ricaurte GA; DeLanney LE; Irwin I; Langston JW
    Brain Res; 1988 Apr; 446(1):165-8. PubMed ID: 2897228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates.
    Ricaurte GA; Forno LS; Wilson MA; DeLanney LE; Irwin I; Molliver ME; Langston JW
    JAMA; 1988 Jul; 260(1):51-5. PubMed ID: 2454332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations.
    Ricaurte GA; Martello AL; Katz JL; Martello MB
    J Pharmacol Exp Ther; 1992 May; 261(2):616-22. PubMed ID: 1374470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The neurochemical and stimulatory effects of putative metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine in rats.
    Yeh SY; Hsu FL
    Pharmacol Biochem Behav; 1991 Jul; 39(3):787-90. PubMed ID: 1723801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
    McNamara R; Kerans A; O'Neill B; Harkin A
    Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices.
    Fitzgerald JL; Reid JJ
    Eur J Pharmacol; 1990 Nov; 191(2):217-20. PubMed ID: 1982265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serotonergic modulation of rat pup ultrasonic vocal development: studies with 3,4-methylenedioxymethamphetamine.
    Winslow JT; Insel TR
    J Pharmacol Exp Ther; 1990 Jul; 254(1):212-20. PubMed ID: 1973197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of ritanserin on the 3,4-methylenedioxymethamphetamine-induced decrease in striatal serotonin concentration and on the increase in striatal neurotensin and dynorphin A concentrations.
    Johnson M; Bush LG; Hanson GR; Gibb JW
    Biochem Pharmacol; 1993 Aug; 46(4):770-2. PubMed ID: 8103327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): assessment using quantitative autoradiography.
    Battaglia G; Sharkey J; Kuhar MJ; de Souza EB
    Synapse; 1991 Aug; 8(4):249-60. PubMed ID: 1681594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurochemical basis of neurotoxicity.
    Gibb JW; Johnson M; Hanson GR
    Neurotoxicology; 1990; 11(2):317-21. PubMed ID: 1978271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine.
    Schmidt CJ
    J Pharmacol Exp Ther; 1987 Jan; 240(1):1-7. PubMed ID: 2433425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.